Drug treatment of rheumatic diseases in the 1990s: Achievements and future developments

Drugs

Volumn 53, Issue 3, 1997, Pages 337-348

  Choy, Ernest H S ^a   Scott, David L ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; CD4 ANTIGEN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; CYTOKINE; DEFLAZACORT; DICLOFENAC; IMMUNOGLOBULIN G; LEFLUNOMIDE; MELOXICAM; METHOTREXATE; MINOCYCLINE; MISOPROSTOL; MONOCLONAL ANTIBODY; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIFAMPICIN; TENIDAP; TUMOR NECROSIS FACTOR ANTIBODY;

ALOPECIA; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BIOTECHNOLOGY; BONE ATROPHY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SELECTIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; IMMUNOMODULATION; MAJOR CLINICAL STUDY; META ANALYSIS; NEPHROTOXICITY; OSTEOPOROSIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYNOVITIS; T LYMPHOCYTE; VERTIGO;

EID: 0030936505     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199753030-00001     Document Type: Article

References (91)

1. Edmonds JP, Scott DL, Furst DE, et al. Anti-rheumatic drugs: a proposed new classification. Arthritis Rheum 1993; 36: 336-9
2. Edmonds JP, Scott DL, Furst DE, et al. New classification of antirheumatic drugs: the evolution of a concept. J Rheumatol 1993; 20: 585-7
3. Felson DT, Andersen JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40
4. Tugwell P, Boers M. OMERACT Conference on outcome measures in rheumatoid arthritis clinical trials. J Rheumatol 1993; 20: 527-90
5. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971; 231: 232-5
6. Mitchell JA, Akarasereenont P, Theimermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993; 90: 11693-7
7. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44: 1-10
8. Ballinger A, Kumar P, Scott DL. Misoprostol and the prevention of gastroduodenal damage due to non-steroidal anti-inflammatory drugs. Ann Rheum Dis 1992; 51: 1089-93
9. Bardhan KD, Bjarnason I, Scott DL, et al. Misoprostol in the prevention and healing of NSAID-associated gastric and duodenal mucosal damage. Br J Rheumatol 1993; 32: 990-5
10. Fenn GC, Morant S, Scott DL. Efficacy of misoprostol in ulcer healing with continued NSAID therapy [abstract]. Br J Rheumatol 1996; 35 Suppl. 1: 222
11. Bolten W, Melo Gomes JA, SteaH, et al. The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. Br J Rheumatol 1992; 31: 753-8
12. Henry D, Lim LLY, Rodriguez LAG, et al. Variability in risk of gastro-intestinal complications with individual anti-inflammatory drugs: results of a collaborative meto-analysis. BMJ 1996; 312: 1563-6
13. Fries J. Toward an understanding of NSAID-related adverse events: the contribution of longitudinal data. Scand J Rheumatol Suppl 1996; 102: 3-8
14. Roth SH. NSAID gastropathy - new understandings. Arch Intern Med 1996; 156: 1623-8
15. Dahl SL. Nabumetone: a 'nonacidic' nonsteroidal antiinflammatory drug. Ann Pharmacother 1993; 27: 456-63
16. Lister BJ, Poland M, DeLapp RE. Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 1993; 95 (2A): 2S-9S
17. Helfgott SM. Nabumetone: a clinical appraisal. Semin Arthritis Rheum 1994; 23: 341-6
18. Roth SH, Bennett R, Caldron P, et al. A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. J Rheumatol 1994; 21: 1118-23
19. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993; 153: 2565-71
20. Engelhardt G, Homma D, Schlegel K, et al. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995; 44: 423-33
21. Engelhardt G, Bogel R, Schnitzler C, et al. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem Pharmacol 1996; 51: 29-38
22. Wojtuliewski JA, Schattenkirchner M, Barcelo P, et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5mg daily and naproxen 750mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996; 35 Suppl. 1: 22-8
23. Mahmud T, Scott DL, Bjarnason I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann Rheum Dis 1996; 55: 211-3
24. Wallance JL, Reuter B, Cicala C, et al. Novel nonsteroidal antiinflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994; 107: 173-90
25. Elliot SN, McKnight W, Cirino G, et al. A nitric-oxide releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995; 109: 524-30
26. Mazzuca SA, Brandt KD, Katz BP, et al. Therapeutic strategies distinguish community based primary care physicians from rheumatologists in the management of osteoarthritis. J Rheumatol 1993; 20: 80-6
27. Dieppe PA, Frankel SJ, Toth B. Is research into the treatment of osteoarthritis with non-steroidal anti-inflammatory drugs misdirected? Lancet 1993; 341: 353-4
28. Bradley JD, Brandt KD, Katz BP, et al. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991; 325: 87-91
29. March L, Irwig L, Schwarz J, et al. n Of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteo-arthritis. BMJ 1994; 309: 1041-5
30. Brandt KD. NSAIDs in the treatment of osteoarthritis. Friends or foes? Bull Rheum Dis 1993; 42: 1-4
31. Brandt KD. Should nonsteroidal anti-inflammatory drugs be used to treat osteoarthritis? Rheum Dis Clin North Am 1993; 19: 29-44
32. Brandt KD. Should osteoarthritis be treated with nonsteroidal anti-inflammatory drugs? Rheum Dis Clin North Am 1993; 19: 697-712
33. Jones AC, Doherty M. The treatment of osteoarthritis. Br J Clin Pharmacol 1992; 3: 357-63
34. Cicuttini FM, Spector TD. Osteoarthritis in the aged: epidemiological issues and optimal management. Drugs Aging 1995; 6: 409-20
35. Scott DL, Berry H, Woolf A, et al. Tiaprofenic acid and symptomatic benefit in osteoarthritis: results from a randomised placebo controlled trial [abstract]. Br J Rheumatol 1995; 34 Suppl. 2: 44
36. Blackburn WD, Heck LW, Loose LD, et al. Inhibition of 5-lipoxygenase product formation and polymorphonuclear cell degranulation by tenidap sodium in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 204-10
37. Sipe JD, Bartle LM, Loose JD. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen: a possible correlate with clinical acute-phase response. J Immunol 1992; 148: 480-4
38. Breedveld F. Tenidap: a novel cytokine-modulating antirheumatic drug for the treatment of rheumatoid arthritis. Scand J Rheumatol 1994; 23 Suppl. 100: 31-44
39. Blackburn WD, Prupas HM, Silverfield JC, et al. Tenidap in rheumatoid arthritis: a 24 week double-blind comparison with hydroxychloroquine-plus-piroxicam and prioxicam alone. Arthritis Rheum 1995; 38: 1447-56
40. Mallya RK, de Beer FC, Berry H, et al. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 1982; 9: 224-8
41. McKenna F. Clinical and laboratory assessment of outcome in rheumatoid arthritis. Br J Rheumatol 1988; 27 Suppl. 1: 12-20
42. Hassell AB, Davis MJ, Fowler PD. The relationship between serial measures of disease activity and outcome in rheumatoid arthritis. Q J Med 1993; 86: 601-7
43. van Leeuwen MA, van der Heijde DMFM, van Rijswijk HH, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis: a comparison of radiological damage, physical disability, joints counts, and acute phase reactants. J Rheumatol 1994; 21: 425-9
44. Otterness I. The value of C-reactive protein measurment in rheumatoid arthritis. Semin Arthritis Rheum 1994; 24: 91-103
45. Wilke WS, Sweeney TJ, Calabrese LH. Early, aggressive therapy for rheumatoid arthritis: concerns, descriptions, and estimate of outcome. Semin Arthritis Rheum 1993; 23 Suppl. 1: 26-41
46. Cash JM, Wilder RL. Refractory rheumatoid arthritis: therapeutic options. Rheum Dis Clin North Am 1995; 21: 1-18
47. Pincus T. Limitations of randomized clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Semin Arthritis Rheum 1993; 23 Suppl 1: 2-10
48. Capell HA, Porter DR, Madhok R, et al. Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient? Ann Rheum Dis 1993; 52: 423-8
49. Kremer JM, Phelps CT. Long-term prospective study ofthe use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992; 35: 138-45
50. Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-Month update. Arthritis Rheum 1992; 35 (2): 129-37
51. Tishler M, Caspi D, Yaron M. Long-term experience with low dose methotrexate in rheumatoid arthritis. Rheumatol Int 1993; 13: 103-6
52. Alarcon GS, Lopez-Mendez A, Walter J, et al. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. J Rheumatol 1992; 19: 1868-73
53. Tugwell P, Bombardier C, Gent M, et al. Low dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335: 1051-5
54. Dougados M. Cyclosporin in rheumatoid arthritis. Clin Exp Rheumatol 1994; 12 Suppl. 11: S75-8
55. Wells G, Tugwell P. Cyclosporin A in rheumatoid arthritis: overview of efficacy. Br J Rheumatol 1993; 32 Suppl. 1: 51-6
56. Forre O, Norwegian Arthritis Study Group. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporin: results of a 48-week multicentre study comparing low dose cyclosporin with placebo. Arthritis Rheum 1994; 37: 1506-12
57. Pasero G, Prioli F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996; 39: 1006-15
58. van den Borne BE, Landewe RB, Goei The HS, et al. Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis. Br J Clin Pharmacol 1995; 39: 172-5
59. Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA486, with potential antirheumatic activity: I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol 1985; 7: 7-18
60. Bartlett RR, Dimitrijevic M, Mattar T, et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991; 32: 10-21
61. Bartlett RR, Anagnostopules H, Zielinski T, et al. Effects of leflunomide on the immune response and models of inflammation. Springer Semin Immunopathol 1993; 14: 381-94
62. Mladenovic V, Domlian Z, Rozman B, et al. Safely and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1995; 38: 1595-603
63. Barron KS, Sher MR, Silverman ED. Intravenous immunoglobulin therapy: magic or black magic. J Rheumatol 1992; 33 Suppl.: 94-7
64. Tumiati B, Casoli P, Veneziani M, et al. High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 1126-33
65. Sany J. Intravenous immunoglobulin therapy for rheumatic diseases. Curr Opin Rheumatol 1994; 6: 305-10
66. Kloppenburg M, Breedveld FC, Terwiel JP, et al. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum 1994; 37: 629-36
67. Tilley BC, Alarcon GS, Heyse SP, et al. Minocycline in rheumatoid arthritis. A48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med 1995; 122: 81-9
68. Paulus HE. Minocycline treatment of rheumatoid arthritis. Ann Intern Med 1995; 122: 147-8
69. Breedveld FC, Dijkmans BA, Mattie H. Minocycline treatment for rheumatoid arthritis: an open dose finding study. J Rheumatol 1990; 17: 43-6
70. Langevitz P, Bank I, Zemer D, et al. Treatment of resistant rheumatoid arthritis with minocycline: an open study. J Rheumatol 1992; 19: 1502-4
71. McConkey B, Situnayake RD. Rifampicin in rheumatoid arthritis [abstract]. J Rheumatol 1991; 18: 784
72. Cox NL, Prowse MV, Maddison MC, et al. Treatment of early rheumatoid arthritis with rifampicin. Ann Rheum Dis 1992; 51: 32-4
73. Borg AA, Davis MJ, Fowler PD, et al. Rifampicin in early rheumatoid arthritis. Scand J Rheumatol 1993; 22: 39-42
74. Corkill MM, Kirkham BW, Chikanza IC, et al. Intra-muscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: a 24 week randomised controlled trial. Br J Rheumatol 1990; 29: 274-9
75. Hansen TM, Kryger P, Elling H, et al. Double blind placebo controlled trial of pulse treatment with methylprednisolone combined with disease modifying drugs in rheumatoid arthritis. BMJ 1990; 301: 268-70
76. Kirwan J. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 142-6
77. Markham A, Bryson HM, Deflazacort: a review ot its pharmacological properties and therapeutic efficacy. Drugs 1995 Aug; 50 (2): 317-33
78. Avioli LV. Potency ratio - a brief synopsis. Br J Rheumatol 1993; 32 Suppl. 2: 24-6
79. Messina OD, Barreira JC, Zanchetta JR, et al. Effect of low doses ot deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis. J Rheumatol 1992; 19: 1520-6
80. Hall GM, Daniels M, Doyle DV, et al. Effect of hormone replacement therapy on hone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994; 37: 1499-505
81. Hall GM, Spector TD, Delmas PD. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy. Arthritis Rheum 1995; 38: 902-6
82. Eggelmeijer F, Papapoulos SE, van Paassen HC, et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized double-blind trial. Arthritis Rheum 1996; 39: 396-402
83. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporin and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333: 137-41
84. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681-90
85. Elliott MT, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10
86. Elliott MJ, Maim RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alph (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-7
87. Moreland LW, Pratt PW, Bucy RP, et al. Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts. Arthritis Rheum 1994; 37: 834-8
88. Choy EHS, Pitzalis C, Cauli A, et al. The amount of anti-CD4 monoclonal antibody entering the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum 1996; 39: 52-6
89. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of retractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule I. Arthritis Rheum 1994; 37: 992-9
90. Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993; 261: 1727-30
91. Sieper J, Kary S, Sorensen H, et al. Oral type II collagen treatment in early rheumatoid arthritis: a double-blind, placebo-controlled, randomized trial. Arthritis Rheum 1996; 39: 41-51